New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
07:15 EDTXON, ZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
News For ZIOP;XON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
19:31 EDTZIOP, XONOn The Fly: After Hours Movers
UP AFTER EARNINGS: Progress Software (PRGS), up 1%. ALSO HIGHER: Repros Therapeutics (RPRX), up 21.9% after announcing acceptance for filing of NDA its enclomiphene citrate product... TCP International (TCPI), up 13.7% after announcing that product validation is proceeding as expected... Intrexon (XON), up 2.4% after signing a CRADA with NCI for RTS platform. DOWN AFTER EARNINGS: Sigma Designs (SIGM), down 2.8%... Micron Technology (MU), down 1.7%. ALSO LOWER: Conatus Pharmaceuticals (CNAT), down 4.4% after filing to sell common stock... TrueCar (TRUE), down 1.8% after being initiated with a Sell at B. Riley... ZIOPHARM Oncology (ZIOP), down 1.8% after filing to sell 11.72M shares of common stock for holders.
18:50 EDTZIOPZiopharm files to sell 11.72M shares of common stock for holders
16:19 EDTXONIntrexon signs CRADA with NCI for RTS platform
Intrexon has signed a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, part of the National Institutes of Health, for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System, or RTS, platform for the treatment of solid tumor malignancies. The principal goal of the CRADA is to develop and evaluate improved adoptive cell transfer-based immunotherapies, or ACT, using NCI proprietary methods for the identification of autologous peripheral blood lymphocytes, or PBL, possessing naturally occurring anti-tumor activity combined with Intrexon's RTS gene switch for introducing spatially and temporally controlled interleukin-12 expression.
March 30, 2015
10:10 EDTXON, ZIOPMizuho says scale, speed of Intrexon-Ziopharm deal a positive
Subscribe for More Information
09:27 EDTZIOP, XONOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTXONIntrexon, Merck Serono announce agreement for CAR-T development
Subscribe for More Information
08:12 EDTZIOP, XONZiopharm-Intrexon announce collaboration with Merck KGaA for CAR-T products
ZIOPHARM Oncology (ZIOP) and Intrexon (XON) announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell, or CAR-T, products with Merck Serono, the biopharmaceutical division of Merck KGaA (MKGAY). Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM. Under the collaboration Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreement with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug stage, the programs will be transferred to Merck Serono for clinical development and commercialization. ZIOPHARM and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. ZIOPHARM's other oncology programs will continue through its Exclusive Channel Collaboration with Intrexon.
March 27, 2015
12:33 EDTXONLegg Mason's Miller says Intrexon, Amazon two of largest positions
12:28 EDTZIOP, XONIntrexon, Ziopharm mentioned as stock picks by Bill Miller on CNBC
March 25, 2015
11:01 EDTZIOPZiopharm May volatility elevated at 129
Ziopharm April call option implied volatility is at 123, May is at 129, July is at 106; compared to its 26-week average of 120 according to Track Data, suggesting large April price movement.
March 23, 2015
06:04 EDTZIOPStocks with implied volatility above IV index mean; ZIOP BBRY
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use